P&F Products & Features Acquires AVVie

August 7, 2026—P&F Products & Features GmbH, headquartered in Vienna, Austria, announced the acquisition of AVVie GmbH, developer of the AngelValve augmentation system, a transcatheter platform for the treatment of mitral valve disease in patients with limited or no treatment options.

AVVie, based in Vienna, was founded by Professor Werner Mohl, MD, noted the press release.

According to P&F, the combination of AVVie’s research and development infrastructure and intellectual property with P&F’s global capabilities in product development, clinical and regulatory affairs, manufacturing, and commercialization will position the company to accelerate innovation and shorten development timelines.

“The acquisition of AVVie reflects our continued commitment to advancing breakthrough structural heart therapies,” commented P&F CEO Katharina Kiss, MD, in the company’s press release. “By combining AVVie’s engineering excellence with P&F’s expertise in clinical trial development and regulatory execution, we are well positioned to advance the AngelValve platform and deliver meaningful innovation for physicians and patients worldwide. This acquisition represents another important step toward our vision of becoming a global leader in structural heart therapy.”

Siegfried Einhellig, COO, President, and Head of R&D at P&F, added, “This combination brings together outstanding engineering talent and proven development capabilities. We’re excited to transform this innovation into a successful therapy.”